Abstract 246P
Background
To study the main causes of neglect of advanced cervical cancer (CC) in Uzbekistan based on the results of a survey of advanced stage cervical cancer patients. The questionnaire was analyzed in 3 directions: “patient delay”, “doctor delay”, “delay of treatment”.
Methods
200 patients with advanced cervical cancer were included in the analysis, including: IIA-B stage-17%; IIIA-B stage 80%; IVA stage - 3%. Descriptive analyses were provided with the WHO questionnaire, adopted for local use, which should explore the possible barriers of early detection of cervical cancer.
Results
In the questionnaire analysis, the following results were obtained in the direction of “doctor delay”: 1. Which doctor did you talk about the symptoms of the disease? General practioner - 8%, gynecologist - 90%, private doctor - 2%; 2. Prior to the establishment of diagnosis contacted doctor: once - 22%, twice - 29%, 3 times and more - 49%. 3. How many times did you have a doctor before starting chemotherapy: Never - 86%, 3 or more times 14%. 4. Some aspects of the treatment surprised patients, no one warned: yes-56%, no-54%; I can easily ask doctor about the disease: Yes-45%, no-55%. 5. Appeal to the doctors before the establishment of diagnosis: twice - 29%, 3 and more time - 49%; To which specialist did you first tell about the symptoms of the disease: Physician - 97%, nurse - 2%, healer - 1%. 6. How many times have been in doctor with relatives: Never -37%; once - 19%; twice - 24%; 3 and more times - 20%. 7. Where you underwent the necessary examinations: State clinic - 70%; private clinic - 30%.
Conclusions
The main reasons for the neglect of cervical cancer in the direction of “doctor delay” are: Weak awareness of general practitioners; Unsatisfactory in forming patients about the severity of the disease, inability to enter the patient's trust; Absence or low level of psychological support of patients; Problems of timely referral of patients to an oncologist; Problems of deontology in the chain: doctor-diagnosis-patient. Elimination of the above-mentioned main causes will lower the incidence and mortality from cervical cancer and improve treatment outcomes, preventing disability of women.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nargiza Zakhirova.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract